ORLANDO, Fla. and PALO ALTO, Calif., June 11, 2026 /PRNewswire/ -- Periscan, an early pioneer in continuous security validation, today announced its return as...
Liyam Chitayat awarded an O'Shaughnessy Fellowship to genetically engineer mitochondria, the power source and control room inside cellsGREENWICH, Conn., June 11, 2026 /PRNewswire/ --...
Recognition affirms Binance's position as a leading CeFi platform built on scale, security, and user trustABU DHABI, UAE, June 11, 2026 /CNW/ -- Binance,...
Funding Fuels Gourmet Convenient Coffee's Next Chapter: New SKUs, Military Channel Entry, and a Founder-Led, Digital-First Growth StrategyCHICAGO, June 11, 2026 /PRNewswire/ -- Diamond...
JERICHO, N.Y., June 11, 2026 (GLOBE NEWSWIRE) -- Kimco Realty® (NYSE: KIM) today announced that its operating subsidiary, Kimco Realty OP, LLC (“Kimco OP”), priced its offering of $525,000,000 aggregate principal amount of 3.50% exchangeable senior notes due 2031 (the “notes”) in a private offering to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). The offering size was increased from the previously announced offering size of $500,000,000 aggregate principal amount of notes. Kimco Realty Corporation (“Kimco”) will fully and unconditionally guarantee the notes on a senior, unsecured basis. The issuance and sale of the notes are scheduled to settle on June 15, 2026, subject to customary closing conditions. Kimco OP also granted the initial purchasers of the notes an option to purchase, for settlement within a period of 13 days from, and including, the date the notes are first issued, up to an additional $75,000,000 principal amount of notes.
Mid-year update highlights strong execution across the Company's U.S. uranium operations, with an expected 1.6 million pounds of finished U3O8 produced from January through...
Mid-year update highlights strong execution across the Company's U.S. uranium operations, with an expected 1.6 million pounds of finished U3O8 produced from January through...
ZUG, Switzerland, June 11, 2026 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company focused on breakthrough innovations to address significant unmet medical needs in neuro-ophthalmology and ophthalmology, today announced an upcoming presentation at Clinical Trials at the Summit 2026, taking place on June 12-13, 2026, in Las Vegas, Nevada.
ZUG, Switzerland, June 11, 2026 – Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company focused on breakthrough innovations to address significant unmet medical needs in neuro-ophthalmology and ophthalmology, today announced an upcoming presentation at Clinical Trials at the Summit 2026, taking place on June 12-13, 2026, in Las Vegas, Nevada.
XUANCHENG, China, June 11, 2026 /PRNewswire/ -- Huasun Energy, a global leader in heterojunction (HJT) solar technology, has been ranked 12th on TIME's World's...
XUANCHENG, China, June 11, 2026 /PRNewswire/ -- Huasun Energy, a global leader in heterojunction (HJT) solar technology, has been ranked 12th on TIME's World's...